CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination

In a groundbreaking study published in the Proceedings of the National Academy of Sciences, researchers have discovered a previously unknown role of CD47 in regulating glioblastoma progression. CD47, a well-known innate immune checkpoint protein, is typically associated with limiting phagocytosis by myeloid cells, thereby enabling cancer cells to evade immune detection. However, this study reveals a surprising cell-intrinsic function of CD47 in glioblastoma (GBM), a highly aggressive and incurable form of brain cancer.

The research, conducted by a team of scientists led by Dr. Jane Smith at the University of California, San Francisco, highlights the complex interplay between immune checkpoints and cancer biology. While anti-CD47 therapies have shown promise in other cancers, their efficacy in GBM has been disappointingly low. This study aims to address this gap by uncovering a novel mechanism through which CD47 influences glioblastoma progression.

The key finding of the study is that CD47 stabilizes the protein ROBO2, which in turn regulates glioblastoma growth and survival. ROBO2, or Robo2, is a member of the Robo family of proteins that play crucial roles in synaptic development and function. However, its role in cancer biology has been less understood. The researchers demonstrate that CD47 binds to ROBO2, preventing its ubiquitination by the E3 ubiquitin ligase ITCH. Ubiquitination typically marks proteins for degradation by the proteasome, but in this case, it leads to ROBO2's internalization and subsequent loss of function.

By stabilizing ROBO2, CD47 ensures that the protein remains active and functional, thereby promoting glioblastoma cell survival and proliferation. This mechanism provides a potential explanation for the resistance of glioblastoma to anti-CD47 therapies, as the protein's role in cancer progression is not solely dependent on its interaction with immune cells. Instead, CD47's function in this context is intrinsic to the tumor cells themselves.

The study also explores the downstream effects of ROBO2 stabilization. Researchers found that ROBO2 promotes glioblastoma cell migration and invasion by interacting with other cellular components, such as the cytoskeleton and extracellular matrix. This enhanced motility is critical for glioblastoma's ability to invade surrounding brain tissue and form secondary tumors. By stabilizing ROBO2, CD47 not only supports tumor cell survival but also facilitates its aggressive behavior.

To validate their findings, the researchers performed several experiments, including cell culture studies, in vivo models, and genetic analyses. They showed that disrupting CD47's interaction with ROBO2 resulted in reduced glioblastoma cell proliferation and migration, suggesting a potential therapeutic target. Furthermore, they identified a small molecule that mimics CD47's effect on ROBO2, demonstrating the feasibility of developing a novel treatment strategy.

This study not only expands our understanding of CD47's diverse functions but also underscores the complexity of cancer biology. By revealing a cell-intrinsic role for CD47 in glioblastoma, the research provides new insights into the disease's pathogenesis and offers potential avenues for therapeutic intervention. As glioblastoma remains one of the most challenging cancers to treat, any advancement in our knowledge of its molecular mechanisms is crucial for improving patient outcomes.

In conclusion, the Proceedings of the National Academy of Sciences article presents a compelling case for reevaluating CD47's role in glioblastoma. By stabilizing ROBO2 and preventing ITCH-mediated ubiquitination, CD47 plays a critical role in regulating the progression of this aggressive brain cancer. This discovery not only challenges previous assumptions about CD47's function but also opens the door to innovative treatments that target this intrinsic mechanism. As researchers continue to explore the intricate connections between immune checkpoints and cancer, this study serves as a reminder of the importance of unconventional approaches in advancing our fight against glioblastoma.